Southern Research
Southern Research (SR) is a nonprofit preclinical contract research institute that has been bridging basic science and commercial solutions for over 80 years. From pioneering chemotherapy research in collaboration with Memorial Sloan Kettering to generating millions of data points in the global fight against COVID-19, SR has consistently been at the forefront of scientific innovation. Our team of experts excels in transforming cutting-edge science into tangible societal benefits, utilizing comprehensive drug discovery and development capabilities to drive innovation and advance life-saving medical breakthroughs. SR collaborates with over 100 industrial partners, the federal government, and numerous academic institutions to advance the development of life-saving medicines.
Southern Research
What We Do
A statewide initiative offering free genetic testing and personalized health insights to Alabama residents, integrating genomic data with clinical care to improve health outcomes.
A biotech incubator providing state-of-the-art laboratory space, mentorship, and resources to accelerate biotechnology startups in Birmingham.
Alabama’s first industrywide resource for testing and validating energy storage technologies, supporting third-party innovators from utilities, academia, government, and technology companies.
A state-of-the-art facility enabling rapid screening of millions of compounds for drug discovery and development.
A preclinical animal model for evaluating Zika virus infection and testing candidate vaccines and antivirals.
Comprehensive research services targeting infectious diseases, including vaccine and therapeutic development, animal models, and high-containment (BSL-3) capabilities.
Research and development services in oncology, including drug discovery, preclinical testing, and clinical trial support for cancer therapies.
Specialized research programs focused on emerging and rare diseases, supporting drug discovery and development for underserved conditions.
Advanced chemistry services supporting drug discovery, medicinal chemistry, and chemical analysis.
Absorption, distribution, metabolism, excretion (ADME), and in vitro toxicology services for drug development.
High-throughput screening (HTS) services to rapidly test compounds for biological activity, supporting drug discovery pipelines.
Comprehensive bioanalytical services including advanced analytics for drug development and clinical trial support.
Development and utilization of animal models for preclinical research, including infectious disease and oncology studies.
In vivo toxicology studies to assess the safety and efficacy of new compounds and therapeutics.
Pathology services supporting preclinical and clinical research, including histopathology and biomarker analysis.
High-containment laboratory services for research on infectious agents requiring BSL-3 containment.
Research and development of various therapeutic modalities, including small molecules, biologics, and advanced therapies.
Analysis of clinical trial samples to support drug development and regulatory submissions.
Flexible, tailored research strategies crafted specifically for project needs, optimizing outcomes from discovery to clinical implementation.
Infectious Diseases
Show More (2)Regenerative Medicine
Drugs
Key People
Doug Bartels
Director, Strategic Initiatives at dbartels@southernresearch.org, 205-581-2738
Rebecca Boohaker
Director, Strategic Initiatives at rboohaker@southernresearch.org, 205-581-2706
News & Updates
Southern Research has discovered seven FDA-approved anticancer drugs, two of which are on the WHO List of Essential Medicines.
Southern Research was part of a team awarded a $71 million contract to support Redstone Arsenal’s Aviation and Missile Research, Development, and Engineering Center.
Southern Research was awarded two BARDA contracts valued between $45 million and $90 million for nonclinical research services to protect the U.S. against infectious disease and bio-terror threats.
Southern Research annually recognizes outstanding employees for advancing science, technology, and organizational excellence.
Southern Research signed its first licensing agreement in a decade with Bionetix Inc. to develop and potentially commercialize novel epigenetic enzyme inhibitors for cancer therapy.
Southern Research is building a Center for Pandemic Resilience to double lab space for infectious disease research and support Alabama’s biotech corridor.